Research funder · United States
Melanoma Research Alliance
Nonprofit organization in Washington D.C., United States
- Grants since 2016
- 400
- Awarded, last 5 years (where amounts are published)
- 72.1M
- Funded works, last 5 years
- 1 190
- Funded works, all time
- 2 826
Grants
2018–2021 · award
Targeting eIF4A in melanoma persistent cells to prevent resistance
Caroline Robert
2018–2021 · award
Defining and targeting driver events in acral melanoma
Keiran Smalley
2018–2021 · award
Regulating telomerase & telomere homeostasis in Acral Melanoma development
Gavin Robertson
2018–2021 · award
Genetic and Phenotypic Biomarkers to Predict Immune-Related Adverse Events
David Gerber
2018–2021 · award
Autophagy in the Tumor Microenvironment as a Target for Drug Development
Hilary Coller
2018–2021 · award
Isoform-specific targeting of the PI3Ks to overcome cancer immunoresistance
Weiyi Peng
2018–2021 · award
Identifying Genetic Dependencies in Rare Forms of Melanoma
Nicholas Hayward
2018–2021 · award
Commensal microbiota and anti-PD-1 efficacy
Thomas Gajewski
2018–2020 · award
Understanding Cutaneous Immunotherapy-related Adverse Events in Melanoma
Suephy Chen
2018–2021 · award
A novel approach for NF1 mutant melanoma subclassification
Edward Stites
2018–2021 · award
Clinical Features and Biomarkers of Immunotherapy Neurologic Toxicity
Bianca Santomasso
2018–2021 · award
The genomic landscape of individual melanocytes from human skin
Alan Shain
2018–2021 · award
Discovery of Therapeutic Approaches for Ipilimumab-associated Colitis
Kai Wucherpfennig
2018–2021 · award
Next-generation neoantigen-targeting peptide vaccines for melanoma patients
Patrick Ott
2018–2021 · award
Directing adaptive immune responses to non-polymorphic MHCs in melanoma
Forest White
2018–2021 · award
Targeting BRAF/NRAS Wildtype Melanoma with ERBB3 and MEK Inhibition
Melissa Wilson
2018–2021 · award
Telomere crisis in acral melanoma: diagnostic and prognostic potentials
Titia De Lange
2018–2021 · award
LncRNAs as modulators of protein synthesis rewiring in melanoma
Eleonora Leucci
2018–2021 · award
Molecular and immune profiling of acral melanoma from various ethnicities
Phyu Aung
2018–2021 · award
Manipulating Cellular Metabolism to Promote Cancer Immunity in Melanoma
Ku-Lung Hsu
2018–2021 · award
Investigating the mechanistic basis for tumor immunogenicity in melanoma
Nikhil Joshi
2018–2021 · award
Dependence of melanoma metastasis on AMPK-mediated metabolic switch
Elena Piskounova
2018–2021 · award
Patient Focused Therapy for Acral Melanoma
Ruth Halaban
2017–2020 · award
A nanoscale technology for real-time tracking of immunotherapy response
Ashish Kulkarni
2017–2021 · award
Development of novel anti-checkpoint strategies based on nanobodies
Karine Breckpot
2017–2020 · award
PKCa as a Node to Overcome Intrinsic MEK Inhibitor Resistance in Melanoma
Lawrence Kwong
2017–2019 · award
Next generation inhibitors against wild-type and mutant BRAF dimers
Evripidis Gavathiotis
2017–2020 · award
Cell of origin as a driver of heterogeneity in melanoma
Lorenz Studer
2017–2020 · award
Blocking melanoma brain metastasis by targeting the microenvironment
Manuel Valiente
2017–2019 · award
A novel T cell regulatory receptor as a target for cancer therapy
Li Wang
2017–2020 · award
DNA-based biomarkers for melanoma diagnosis and prognostication
Boris Bastian
2017–2021 · award
Epigenetic effectors of responses to immune checkpoint blockade agents
Kunal Rai
2017–2020 · award
Multiplex biomarkers for response to PD-1/PD-L1 checkpoint blockade
Janis Taube
2017–2020 · award
Identification of active drugs for NF1-mutant, BRAF/NRAS-wildtype melanoma
A. Look
2017–2020 · award
Effective melanoma immunity by targeting NK cell checkpoints
Nicholas Huntington
2017–2020 · award
Development of YAP inhibitors to modulate regulatory T cell in melanoma
Fan Pan
2017–2020 · award
Targeting TEAD autopalmitoylation in YAP-dependent uveal melanoma
Xu Wu
2017–2020 · award
"Smart" Nanoparticles for Immunotherapeutic Targeting of the STING Pathway
John Wilson
2017–2020 · award
Phase I/II Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination with Systemic Pembrolizumab in Patients with Metastatic Melanoma
Adi Diab
2017–2020 · award
Non-invasive imaging of the anti-melanoma immune response
Hidde Ploegh